Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SANOFI : Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

04/22/2013 | 01:09am EDT

PRESS RELEASE

Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe - Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine - Lyon, France - April 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN

and NYSE: SNY), announced today that the European Commission approved Sanofi Pasteur's 6-in-
1 pediatric vaccine HexyonTM/Hexacima® (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima® is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name HexyonTM in Western European countries* by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima® in Eastern European countries by Sanofi Pasteur.

"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."

Key benefits of HexyonTM/Hexacima® vaccine:


ę Publicnow 2013
All news about SANOFI
07:00aPRESS RELEASE : BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell The..
DJ
05:22aSANOFI : UBS reaffirms its Buy rating
MD
08/03SANOFI : to acquire Translate Bio; advances deployment of mRNA technology across..
PU
08/03S&P 500 closes at record high as Apple, healthcare stocks help shrug off Delt..
RE
08/03Global markets live: Sanofi, Alphabet, BMW, Ford, Tencent...
08/03Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal
RE
08/03Today on Wall Street: Corporate profits rise by a level not seen since 2009
08/03SECTOR UPDATE : Health Care Stocks Flat To Higher Pre-Bell Tuesday
MT
08/03Wall Street Set for Small Gains, Earnings in Focus
MT
08/03Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal
RE
More news
Financials
Sales 2021 37 031 M 44 002 M 44 002 M
Net income 2021 6 060 M 7 201 M 7 201 M
Net Debt 2021 7 345 M 8 727 M 8 727 M
P/E ratio 2021 17,9x
Yield 2021 3,81%
Capitalization 109 B 129 B 129 B
EV / Sales 2021 3,13x
EV / Sales 2022 2,87x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 86,45 €
Average target price 104,06 €
Spread / Average Target 20,4%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI9.85%128 643
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
ELI LILLY AND COMPANY51.62%232 701
NOVARTIS AG-0.20%224 638